Bladder Cancer

P53 gene deletion occurs in multiple tumors with poor prognosis.

Prostate Cancer

P53 gene deletion occurs in a variety of tumors with poor prognosis;

P53 deletion in prostate cancer is associated with progression and has a high Gleason score.

Chronic lymphocytic leukemia (CLL)

P53 deletion occurs in approximately 17% of B-CLL; these patients have poorer outcomes and shorter survival to conventional single-agent chemotherapy;

For CLL patients with del(17p) are more sensitive to treatment regimens containing alemtuzumab (anti-CD52);

For CLL patients with no del(17p) and del(11q) after FISH detection (17p) and del(11q) after FISH testing, conventional chemotherapy ± immunotherapy is recommended for patients with CLL.

Multiple myeloma (MM)

P53 deletion has a 1/3 incidence in new-onset MM;

implies shortened survival and poor prognosis for patients treated with conventional doses of chemotherapy.